Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1940 Target Snapshot

Voltage-dependent L-type calcium channel subunit alpha-1C · SINGLE PROTEIN · Homo sapiens

760Compounds
329Assays
33Approved Drugs
646.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q13936. Use UniProt Q13936 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q13936 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Voltage-dependent L-type calcium channel subunit alpha-1C as ChEMBL target CHEMBL1940, mapped to UniProt Q13936. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Voltage-dependent L-type calcium channel subunit alpha-1C
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1940
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13936
Voltage-dependent L-type calcium channel subunit alpha-1C
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Voltage-dependent L-type calcium channel subunit alpha-1C is the right protein anchor across sources, using UniProt Q13936 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelVoltage-dependent L-type calcium channel subunit alpha-1C
UniProt AccessionQ13936
Component TypeProtein
Sequence Length2221 aa

Voltage-dependent L-type calcium channel subunit alpha-1C

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Voltage-dependent L-type calcium channel subunit alpha-1C, mapped to UniProt Q13936. Sequence length is 2221 aa.

Mapped IDQ13936
Review nameVoltage-dependent L-type calcium channel subunit alpha-1C
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

33
Approved
5
Phase III
6
Phase II
Assay Mix

Activity Type Distribution

IC50591.0
KI28.0
EC503.0
KD24.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL475534 9.6 Ki 0.25 Clinical
CHEMBL475534 9.59 Kd 0.26 Clinical
CHEMBL193 9.4 Kd 0.4 Approved
CHEMBL159854 9.0 Ki 1.0 Preclinical
CHEMBL193 9.0 Ki 1.0 Approved
CHEMBL1648 8.66 IC50 2.2 Approved
CHEMBL3392281 8.59 Kd 2.6 Preclinical
CHEMBL1726 8.52 IC50 3.0 Approved
CHEMBL104455 8.39 Ki 4.11 Preclinical
CHEMBL23692 8.3 Kd 5.0 Preclinical
Distribution

pChEMBL Value Distribution

66
5.0
38
5.5
31
6.0
17
6.5
13
7.0
14
7.5
3
8.0
3
8.5
3
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIBEFRADIL
CHEMBL45816
Approved 1997
NISOLDIPINE
CHEMBL1726
Approved 1995
ISRADIPINE
CHEMBL1648
Approved 1990
NIMODIPINE
CHEMBL1428
Approved 1988
NICARDIPINE
CHEMBL1484
Approved 1988
NIFEDIPINE
CHEMBL193
Approved 1981
VERAPAMIL
CHEMBL6966
Approved 1981
CLOTRIMAZOLE
CHEMBL104
Approved 1975
TESTOSTERONE
CHEMBL386630
Approved 1972
Assay Landscape

Assay Landscape

329
Total Assays
169
Tested Compounds
4
Assay Types
Binding — 162 assays, 169 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 104 52 5.1
cell-based format 37 51 5.8
cell membrane format 8 18 7.1
assay format 7 27 5.8
tissue-based format 6 21 6.9
Functional — 132 assays, 70 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 131 69 5.5
tissue-based format 1 1 6.3
Toxicity — 19 assays, 10 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 13 4 4.8
cell-based format 6 6 5.0
ADME — 16 assays, 12 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 10 10 4.9
cell-based format 5 1 5.8
assay format 1 1 4.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine